Literature DB >> 21294982

An international perspective on the basis for payment for performance.

Barbara Starfield1, Derelie Mangin.   

Abstract

This discussion paper reflects on the pay-for-performance system in UK general practice - the Quality and Outcomes Framework (QOF) - from an international viewpoint. The QOF intends to bring the best scientific evidence to bear on primary care practice. However, the QOF and patient-centred medicine are often at odds. Inadequacies and commercial bias in the creation of evidence make the scientific basis of the QOF questionable. The framework for the QOF does not align well with the scope of primary care, making its basis as a tool for quality measurement questionable. The extent of impact of the QOF on health outcomes and on equity of health outcomes needs examination. Attention to resolution of patients' problems is an important aim of quality improvement activities. Alternative modes of improving patient care may be better than the QOF.

Entities:  

Mesh:

Year:  2010        PMID: 21294982

Source DB:  PubMed          Journal:  Qual Prim Care        ISSN: 1479-1064


  4 in total

1.  Accountability and primary healthcare.

Authors:  Shaheena Mukhi; Jan Barnsley; Raisa B Deber
Journal:  Healthc Policy       Date:  2014-09

2.  Toward a Theory of a Right to Health: Capability and Incompletely Theorized Agreements.

Authors:  Jennifer Prah Ruger
Journal:  Yale J Law Humanit       Date:  2006

3.  Family medicine model in Turkey: a qualitative assessment from the perspectives of primary care workers.

Authors:  Zeliha Asli Öcek; Meltem Çiçeklioğlu; Ummahan Yücel; Raziye Özdemir
Journal:  BMC Fam Pract       Date:  2014-02-27       Impact factor: 2.497

4.  International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action.

Authors:  Dee Mangin; Gülistan Bahat; Beatrice A Golomb; Laurie Herzig Mallery; Paige Moorhouse; Graziano Onder; Mirko Petrovic; Doron Garfinkel
Journal:  Drugs Aging       Date:  2018-07       Impact factor: 3.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.